Overall survival (OS) in patients (pts) with EGFR T790M-positive advanced non-small cell lung cancer (NSCLC) treated with osimertinib: Results from two phase II studies

Authors:

Abstract
Background: Osimertinib is an oral, potent, CNS active, irreversible EGFR-TKI approved to treat pts with T790M-positive advanced NSCLC. Here we present updated data from a pre-planned pooled analysis of Phase II studies: AURA extension (NCT01802632), AURA2 (NCT02094261).